The competitive award was granted by USAMRDC in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium working in partnership with the Department of Defense (DoD). The award is expected to provide Altimmune sufficient funding to cover the entire cost of conducting this clinical trial.
Declaration of interests N.P.K. is a co-founder, shareholder, and chair of the scientific advisory board of Icosavax. The remaining authors declare no competing interests. Amsterdam UMC has filed a patent application concerning the SARS-CoV-2 mAbs used here (Brouwer et al., 2020). N.P.K. has a nonprovisional US patent (no. 14/930,792) related to I53-50 (Bale et al., 2016).